Overview
Ilkka Harvima practices in Kuopio, Finland. Harvima is rated as an Advanced expert by MediFind in the treatment of Hypersensitivity Vasculitis. Their top areas of expertise are Squamous Cell Skin Carcinoma, Actinic Keratosis, Bowen's Disease, and Basal Cell Skin Cancer.
Their clinical research consists of co-authoring 54 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Hypersensitivity Vasculitis.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Squamous Cell Skin CarcinomaHarvima isDistinguished. Learn about Squamous Cell Skin Carcinoma.
- Advanced
- Actinic KeratosisHarvima isAdvanced. Learn about Actinic Keratosis.
- Basal Cell Skin CancerHarvima isAdvanced. Learn about Basal Cell Skin Cancer.
- Bowen's DiseaseHarvima isAdvanced. Learn about Bowen's Disease.
- Hypersensitivity VasculitisHarvima isAdvanced. Learn about Hypersensitivity Vasculitis.
- Experienced
- Atopic DermatitisHarvima isExperienced. Learn about Atopic Dermatitis.
- ErysipelasHarvima isExperienced. Learn about Erysipelas.
- KeloidsHarvima isExperienced. Learn about Keloids.
- MelanomaHarvima isExperienced. Learn about Melanoma.
- Neuroendocrine TumorHarvima isExperienced. Learn about Neuroendocrine Tumor.
- PsoriasisHarvima isExperienced. Learn about Psoriasis.